Appropriate management of adverse events due to chemotherapy is a key factor in continuation of chemotherapy for malignant tumors. Of all chemotherapy-related adverse events, emesis is the most common form of non-hematological toxicity. Although there are differences in severity, 70--80% of patients experience emesis during chemotherapy.[@b1] If chemotherapy-induced nausea and vomiting (CINV) is not controlled, patients may lose their motivation to continue treatment, resulting in refusal of chemotherapy or reduced compliance that ultimately shortens survival. CINV also negatively impacts the quality of life (QOL) of cancer patients.[@b2],[@b3] Thus, suppressing CINV is a crucial aspect of successful chemotherapy.

The Perugia Antiemetic Consensus Guideline Meeting established standards for classifying chemotherapy agents into four groups according to emetic risk: highly-emetogenic chemotherapy (HEC), moderately-emetogenic chemotherapy (MEC), low-emetogenic chemotherapy (LEC) and those with minimal risk.[@b4] These classifications are currently used in many guidelines. MEC indicates risk in 30--90% of patients. Combined 5-hydroxytryptamine 3 (5-HT3) receptor antagonists and dexamethasone (DEX) are recommended for prophylaxis of acute (within 24 h of chemotherapy administration) emesis, while DEX alone is recommended for control of delayed emesis (more than 24 h post-administration).[@b5]

Palonosetron (PALO) is a novel 5-HT3 receptor antagonist that has exhibited high selective affinity for the 5-HT3 receptor in various experimental models. Mean half-life of the drug was approximately 40 h after both i.v. and p.o. administration in a clinical pharmacological study of PALO in healthy adults, or 4--10 times longer than other 5-HT3 receptor antagonists.[@b6] This long half-life and high affinity for 5-HT3 receptors are the main benefits of PALO. A phase III double-blind comparative trial was performed in Japan with PALO and granisetron in cancer patients receiving HEC; this study demonstrated non-inferiority for PALO in terms of the complete response (CR) rate for acute vomiting and superiority for PALO in terms of the CR rate for delayed vomiting.[@b7]

This suggests the possibility of eliminating the day 2 and 3 DEX doses to control delayed CINV when using a PALO combination during chemotherapy. Previous reports have shown non-inferiority of day 1 PALO and day 1 DEX against day 1 PALO and day 1--3 DEX in patients receiving MEC (including anthracycline and cyclophosphamide \[AC\]).[@b8],[@b9]

Given the above, the present study was performed to determine whether day 2 and 3 DEX doses to control delayed vomiting could be eliminated in non-AC MEC in combination with PALO. Demonstration of non-inferiority of anti-emetic effects after elimination of day 2 and 3 DEX doses would help prevent overtreatment with DEX and help alleviate associated adverse events and other forms of patient burden, ultimately contributing to increased patient QOL.

Patients and Methods
====================

Study design
------------

The present study was a multicenter, open-label, non-inferiority, randomized comparative phase III trial, with study centers consisting of 18 locations in Hokkaido, Japan. The enrollment phase lasted from April 2011 to March 2013. Enrollment subjects were randomly allocated to one of two groups (control or study treatment group) following confirmation that they met all inclusion criteria and did not meet any exclusion criteria. Randomization was performed according to the minimization method using the four factors of: study center, chemotherapy regimen (oxaliplatin \[L-OHP\]-based, irinotecan \[CPT-11\]-based, carboplatin \[CBDCA\]-based or other), sex (male or female) and age (under 55 years of age or 55 years and older).

In accordance with Ethical Guidelines for Clinical Studies, clinical research ethical review boards at all institutions reviewed and approved the study prior to study initiation. The study was also registered with the UMIN Clinical Trials Registry (UMIN000009403). Finally, in accordance with Japanese ethical guidelines on clinical research and at the request of the ethical review board of Hokkaido University Hospital, clinical research insurance was obtained to compensate subjects in case of damage to health.

Subjects
--------

Written informed consent was obtained from all subjects prior to enrollment. Primary inclusion criteria were age of 20 years or older, diagnosis of malignant tumor, no history of chemotherapy (patients who had received LEC were permitted), planned administration of non-AC MEC, and sufficient marrow, renal and kidney function to tolerate chemotherapy. Primary exclusion criteria were a history of grade 2 or higher nausea prior to enrollment, previous PALO use, planned administration of MEC on multiple sequential days, and planned administration of cisplatin (CDDP) regardless of dose.

Outcomes
--------

The objective of the current study is to assess the optimum dosage method for DEX when used in combination with PALO. The primary endpoint was overall CR rate, while secondary endpoints were CR rate (acute and delayed phases), complete control (CC) rate (overall, acute, and delayed) and frequency/severity of adverse events. The total control (TC) rate was not prescribed in the protocol, but we assessed it as a *post hoc* analysis. "Overall" is defined as up to 120 h from chemotherapy administration, "acute" is defined as the phase up to 24 h post-administration, and "delayed" is defined as the phase 24--120 h post-administration.

Gastrointestinal (GI) symptom diaries were used to evaluate efficacy. Patients received a complete explanation of the GI symptom diaries, and were then requested to make entries every 24 h up to 120 h post-administration. The diaries enabled entry of the number of vomiting events and severity of nausea. Nausea was evaluated according to a four-step Likert scale.

The CR rate is defined as the proportion of subjects in the analysis set with no emetic events and no anti-emetic measures. The CC rate is the proportion of subjects with no emetic events, no anti-emetic measures, and either no nausea or mild nausea. Finally, TC rate is the proportion of subjects with no emetic events, no anti-emetic measures and no nausea. Adverse events were evaluated according to Common Terminology Criteria for Adverse Events v. 4.0. Exacerbation of symptoms by one grade level or higher compared to before initiation of the study is considered an adverse event; incidence rates of adverse events for which a causal relationship with the study treatment could not be denied were calculated for the analysis population.

Treatments
----------

The following treatments were performed for each group. The control group received 9.9 mg DEX i.v. followed by 0.75 mg PALO i.v. prior to MEC administration. Counting the day of MEC treatment as day 1, DEX was administered on days 2 and 3 either p.o. (8 mg) or i.v. (6.6 mg). The study treatment group received 9.9 mg DEX i.v., followed by 0.75 mg PALO i.v. prior to MEC. Thereafter, MEC only was administered. We held medical interviews when collecting patients' diaries, and asked the patients whether they had taken the steroid medication on days 2 and 3. The study protocol allowed the use of 5-HT3 receptor antagonists as antiemetics, corticosteroids (excluding dexamethasone), antidopaminergic agents, phenothiazine tranquilizers, antihistamines, and benzodiazepines as rescue drugs, which were equally available to all subjects. It prohibited the use of NK1 receptor antagonists, SSRI and SNRI.

Statistical analysis and sample size calculation
------------------------------------------------

The primary purpose of the present study was to evaluate the non-inferiority of the study treatment group compared to the control group in subjects receiving non-AC MEC. The primary analysis was performed by applying a logistic regression model on the full analysis set using all allocation factors excluding study center (chemotherapy treatment, sex and age) as covariates to estimate the difference in the overall CR rate between the two groups (study treatment group − control group) and its two-sided Wald-type 95% confidence interval (CI). The margin of non-inferiority was set at 15%, and non-inferiority was assessed by checking whether the lower bound of the 95% CI of the difference of the overall CR rate included −15%. The margin of 15% corresponds to approximately 1.25 based on the risk ratio scale because the expected CR rate was set at 70%. The non-inferiority margin of 1.25 is not very large in general. In addition, previous similar studies[@b8],[@b9] also set the non-inferiority margin at 15%. Therefore, we have assumed that the non-inferiority margin of 15% is acceptable in this setting. This was a non-inferiority study, so a one-sided significance level of 2.5% was used. Treatment-by-subgroup interaction was assessed using the Gail--Simon test.[@b10] All efficacy outcomes were assessed for the intention-to-treat population, which included all randomized patients except those who did not receive any treatment at all or who were ineligible after randomization. Subjects who have no data after randomization were excluded from the safety population.

The target sample size was determined in the following manner. In a Japanese dose-response trial [@b11] of PALO in MEC patients, the overall CR rate for the PALO 0.75-mg group was 69.6%. The number of subjects required per group was calculated at 147 assuming expected CR rates of 70% for both groups, a non-inferiority margin of 15%, statistical power of 80%, a one-sided alpha error of 2.5% and, because dynamic allocation was used, a multiple correlation coefficient of 0 for allocation factors used in the logistic regression modeling and groups. Therefore, the target sample size was set at 150 per group, or a total of 300, to allow for some dropouts.

Results
=======

Patient characteristics and baseline demographics
-------------------------------------------------

Figure[1](#fig01){ref-type="fig"} shows the CONSORT diagram for the study. Out of 308 subjects enrolled, 154 were allocated randomly to the control group and the study treatment group. Of these, 305 were included in the efficacy analysis population. Of the three subjects excluded from the efficacy analysis population, 2 withdrew prior to protocol treatments while 1 was discovered not to meet inclusion requirements. The safety analysis population consisted of 298 subjects.

![CONSORT diagram.](cas0106-0891-f1){#fig01}

No significant differences were observed in the 308 randomly-allocated subjects in terms of allocation factors (Table[1](#tbl1){ref-type="table"}). Most subjects were 55 years of age or older (85.0%). While most subjects used an L-OHP-based chemotherapy regimen (72.8%), only 12.1% used a CBDCA-based regimen.

###### 

Baseline demographics and clinical characteristics

                                                               Control group[†](#tf1-1){ref-type="table-fn"} (*n *=* *154)   Study treatment group[‡](#tf1-1){ref-type="table-fn"} (*n *=* *151)
  ------------------------------------------------------------ ------------------------------------------------------------- ---------------------------------------------------------------------
  Gender, *n* (%)                                                                                                            
   Female                                                      67 (43.5)                                                     65 (43.0)
   Male                                                        87 (56.5)                                                     86 (57.0)
  Age, *n* (%)                                                                                                               
   \<55 years                                                  22 (14.3)                                                     24 (15.9)
   ≥55 years                                                   132 (85.7)                                                    127 (84.1)
   Mean (min--max)                                             64.0 (23--88)                                                 64.1 (34--85)
  Alcohol consumption within 180 days of enrollment, *n* (%)                                                                 
   Yes                                                         68 (44.2)                                                     70 (46.4)
   No                                                          80 (51.9)                                                     77 (51.0)
   Unknown                                                     6 (3.9)                                                       4 (2.6)
  Chemotherapy regimen, *n* (%)                                                                                              
   Oxaliplatin-based                                           112 (72.7)                                                    110 (72.8)
   Irinotecan-based                                            20 (13.0)                                                     21 (13.9)
   Carboplatin-based                                           19 (12.3)                                                     18 (11.9)
   Other                                                       3 (1.9)                                                       2 (1.3)

†Control group: Palonosetron day 1+ dexamethasone days 1--3. ‡Study treatment group: Palonosetron day 1+ dexamethasone day 1.

Efficacy
--------

The primary endpoint of the overall CR rate for the 305 subjects in the efficacy analysis population was 63.6% (98/154) in the control group and 66.2% (100/151) in the study treatment group. The difference in CR rates between the two groups according to the logistic regression model with allocation factors as covariates was 2.5% (95% CI: −7.8% to 12.8%; *P-value* for non-inferiority test = 0.0004), demonstrating non-inferiority of the study treatment group. There were no large differences between the two groups according to phase (Table[2](#tbl2){ref-type="table"}). Subgroup analysis of the CR rate according to age (below 55 years or 55 years and above), sex (male or female) or chemotherapy (L-OHP-based, CPT-11-based, CBDCA-based or other) revealed a beneficial trend for the control group, with −25.8% for below 55 years of age (*P-value* for interaction = 0.081) in spite of no statistically significant treatment-by-subgroup interaction in this study (Table[3](#tbl3){ref-type="table"}).

###### 

Efficacy

                                                                    Control group[†](#tf2-1){ref-type="table-fn"} (*n *=* *154)   Study treatment group[‡](#tf2-1){ref-type="table-fn"} (*n *=* *151)   Difference between arms (95% CI)
  ----------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------- ----------------------------------
  Complete response[§](#tf2-1){ref-type="table-fn"} rate, *n* (%)                                                                                                                                       
   Overall (0--120 h)                                               98 (63.6)                                                     100 (66.2)                                                            2.5% (−7.8--12.8%)
   Acute (0--24 h)                                                  142 (92.2)                                                    141 (93.4)                                                            1.2% (−4.6--7.0%)
   Delayed (24--120 h)                                              100 (64.9)                                                    101 (66.9)                                                            1.9% (−8.4--12.2%)
  Complete control[¶](#tf2-1){ref-type="table-fn"} rate, *n* (%)                                                                                                                                        
   Overall (0--120 h)                                               95 (61.7)                                                     98 (64.9)                                                             3.2% (−7.2--13.5%)
   Acute (0--24 h)                                                  142 (92.2)                                                    141 (93.4)                                                            1.2% (−4.6--7.0%)
   Delayed (24--120 h)                                              97 (63.0)                                                     99 (65.6)                                                             2.6% (−7.9--12.9%)
  Total control[††](#tf2-1){ref-type="table-fn"} rate, *n* (%)                                                                                                                                          
   Overall (0--120 h)                                               73 (47.4)                                                     75 (49.7)                                                             2.3% (−8.5--13.1%)
   Acute (0--24 h)                                                  134 (87.0)                                                    129 (85.4)                                                            −1.6% (−9.3--6.2%)
   Delayed (24--120 h)                                              74 (48.1)                                                     76 (50.3)                                                             2.3% (−8.9--13.5%)

†Control group: Palonosetron day 1+ dexamethasone days 1--3. ‡Study treatment group: Palonosetron day 1+ dexamethasone day 1. §Complete response: No emetic events and no anti-emetic measures (nausea allowed). ¶Complete control: No emetic events, no anti-emetic measures, and no nausea or mild nausea. ††Total control: No emetic events, no anti-emetic measures and no nausea. CI, confidence interval.

###### 

Subgroup analysis of complete response rates by allocation factors

                                  Control group[†](#tf3-1){ref-type="table-fn"} (*n *=* *154)   Study treatment group[‡](#tf3-1){ref-type="table-fn"} (*n *=* *151)   Difference between arms (95% CI)   Interaction test
  ------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------- ------------------
  Age, *n* (%)                                                                                                                                                                                           
   Under 55 years                 13 (59.1)                                                     8 (33.3)                                                              −25.8% (−53.7--2.1%)               0.081
   55 years or older              85 (64.4)                                                     92 (72.4)                                                             8.1% (−3.2--19.3%)                 
  Sex, *n* (%)                                                                                                                                                                                           
   Male                           62 (71.3)                                                     65 (75.6)                                                             4.3% (−8.8--17.5%)                 0.500
   Female                         36 (53.7)                                                     35 (53.9)                                                             0.1% (−16.9--17.1%)                
  Chemotherapy regimen, *n* (%)                                                                                                                                                                          
   Oxaliplatin-based              71 (63.4)                                                     76 (69.1)                                                             5.7% (−6.7--18.1%)                 0.351
   Irinotecan-based               13 (65.0)                                                     14 (66.7)                                                             1.7% (−27.4--30.7%)                
   Other                          14 (63.6)                                                     10 (50.0)                                                             −13.6% (−43.4--16.1%)              

†Control group: Palonosetron day 1+ dexamethasone days 1--3; ‡Study treatment group: Palonosetron day 1+ dexamethasone day 1. CI, confidence interval.

Analysis on the influence of subject background factors showed adjusted odds ratio of sex (female *vs* male) 0.57 (95% CI: 0.33--1.00; *P* = 0.049), per 10-year increments 1.44 (95% CI: 1.12--1.85; *P* = 0.005), alcohol (yes *vs* no) 1.56 (95% CI: 0.88--2.76; *P* = 0.125), complication (yes *vs* no) 0.53 (95% CI: 0.28--0.98; *P* = 0.042), regimen (CPT-11 *vs* others) 1.47 (95% CI: 0.56--3.87; *P* = 0.652) and regimen (L-OHP *vs* others) 1.50 (95% CI = 0.73--3.07; *P* = 0.462).

Adverse events
--------------

Proportions of incidence of adverse events for the 298 subjects in the safety analysis population were 30.0% in the control group and 23.0% in the study treatment group, resulting in no significant difference between the two groups. Primary adverse events observed were constipation (control group, 14.0%; study treatment group, 12.2%), hiccups (control group, 8.0%; study treatment group, 2.7%), anorexia (control group, 5.8%; study treatment group, 3.6%), and elevated ALT (control group, 5.4%; study treatment group, 5.4%) (Table[4](#tbl4){ref-type="table"}). The incidence rate of adverse events that might have been attributable to the steroid medication, such as abdominal pain and hiccups, tended to be lower in the day 1 group, but no statistical significance was observed.

###### 

Treatment-related adverse events (AE)

  *n* (%)          Control group[†](#tf4-1){ref-type="table-fn"} (*n *=* *150)   Study treatment group[‡](#tf4-1){ref-type="table-fn"} (*n *=* *148)                                   
  ---------------- ------------------------------------------------------------- --------------------------------------------------------------------- --------- ----------- --------- -------
  All AE           45 (30)                                                       9 (6)                                                                 1 (0.7)   34 (23)     7 (4.7)   0 (0)
  Elevated AST     7 (4.7)                                                       1 (0.7)                                                               0 (0)     7 (4.8)     1 (0.7)   0 (0)
  Elevated ALT     8 (5.4)                                                       1 (0.7)                                                               1 (0.7)   8 (5.4)     1 (0.7)   0 (0)
  Constipation     21 (14)                                                       1 (0.7)                                                               0 (0)     18 (12.2)   2 (1.4)   0 (0)
  Abdominal pain   6 (4)                                                         0 (0)                                                                 0 (0)     2 (1.4)     0 (0)     0 (0)
  Hiccups          12 (8)                                                        4 (2.7)                                                               0 (0)     4 (2.7)     1 (0.7)   0 (0)
  Anorexia         8 (5.8)                                                       3 (2.2)                                                               0 (0)     5 (3.6)     1 (0.7)   0 (0)

†Control group: palonosetron day 1+ dexamethasone days 1--3. ‡Study treatment group: palonosetron day 1+ dexamethasone day 1.

Discussion
==========

This study successfully demonstrated non-inferiority of DEX administration on day 1 only compared to days 1--3 when used in combination with PALO during non-AC MEC. DEX is widely used for CINV in clinical situations; a meta-analysis of 32 studies covering 5613 subjects resulted in a risk ratio of 1.26 for the acute phase and 1.29 for the delayed phase when comparing the DEX group to the no-treatment group, demonstrating anti-emetic efficacy of the drug.[@b12] However, one draw-back of this analysis is the almost complete lack of non-AC, non-CDDP regimens covered. Furthermore, there is currently no evidence nor consensus on optimal dosages or treatment periods of DEX for delayed emesis.[@b12] Although DEX itself is considered to have mild adverse reactions overall, they include hyperglycaemia, drowsiness, headaches, feeling hot, chills, oral dryness, diarrhea, euphoria, lassitude, upper abdominal pain and rashes. DEX should be avoided in patients with a history of inadequately controlled diabetes mellitus or GI ulcers.

PALO is the only 5-HT3 receptor antagonist that has been demonstrated to be effective against delayed emesis. It is known to have a longer plasma half-life than other 5-HT3 receptor antagonists, but this alone is insufficient to explain efficacy in the delayed phase. Delayed emesis is known as primarily mediated by substance P, whose action on the medullary vomiting center is mediated by the neurokinin 1 receptor. Therefore, inhibiting substance P is key to inhibiting delayed emesis. Basic research on whether or not PALO inhibits substance P has shown that, unlike other 5-HT3 receptor antagonists, the drug does exert inhibitory effects on various reactions with which substance P is involved,([@b13]^)^ a result supporting the findings of the present study.

Eliminating DEX from all anti-emetic therapy using PALO in non-AC MEC is not recommended. Although DEX does cause the adverse events described above, subgroup analysis of the current study warranted that eliminating DEX doses on days 2 and 3 tends to reduce CR rates for subjects under 55 years of age.

Analysis on the influence of subject background factors showed that odds ratio per 10-year increments 1.44 (95% CI: 1.12--1.85) and the age was the significant factor that influenced CR rates. Younger patients are generally considered to be at increased risk of CINV. As similar results were observed in this study, we wish to stress the importance of anti-emetic therapy for younger patients.

Of all the subjects receiving non-L-OHP-based and non-CPT-11-based regimens in this study, 88.1% received carboplatin-based treatment. This drug induces emesis at a higher rate than other MEC,[@b14] and is also considered to have greater prolonged effects in the delayed phase. Emetic risk may also be highly dependent on dosage (area under the curve), so care is required when administering anti-emetic therapy.

However, our study has a limitation. This study is not a double-blind trial but an open label one. We do not deny the possibility that bias may occur. As the results of our study, however, are comparable to those of similar studies[@b8],[@b9] that were conducted abroad, we believe that our results are reproducible and its influence on the results is small. However, it should be remembered that the DEX-related results described here were obtained in combination with PALO, so DEX administration should not be eliminated in combination with other 5-HT3 receptor antagonists. However, the study did demonstrate the usefulness of 0.75 mg PALO as well in the delayed phase of non-AC MEC, results which should help alleviate patient burden associated with excessive treatment of DEX and improve QOL.
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